ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA

RNS Number : 4580B

AstraZeneca PLC

07 October 2015

 

ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA

AstraZeneca has announced the global completion of the divestment of Caprelsa® (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.

Genzyme made an upfront payment to AstraZeneca of $165 million to acquire the global rights to sell and develop Caprelsa, and will make further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. 

The divestment reinforces AstraZeneca's strategic focus on its three main therapy areas. As an asset divestment, the upfront receipt and any subsequent payments for the agreement will be reported in Other Operating Income in the Company's financial statements. The transaction does not impact AstraZeneca's financial guidance for 2015.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler		UK/Global	[phone]
Vanessa Rhodes		UK/Global	[phone]
Ayesha Bharmal		UK/Global	[phone]
Karen Birmingham		UK/Global	[phone]
Jacob Lund		Sweden	[phone]
Michele Meixell		US	[phone]
Investor Enquiries
UK
Thomas Kudsk Larsen	Oncology	[phone]	[phone]
Eugenia Litz	RIA	[phone]	[phone]
Nick Stone	CVMD	[phone]	[phone]
Craig Marks	ING	[phone]	[phone]
Christer Gruvris		[phone]	[phone]
US
Lindsey Trickett	Oncology, ING	[phone]	[phone]
Mitch Chan	Oncology	[phone]	[phone]
Dial / Toll-Free		[phone]	[phone]

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

7 October 2015

-ENDS-

 

END

 

 

MSCEAEEKELKSFAF